

1 **The ratio of BRAFV600E alleles can be used to assess the biological**
2 **behavior of papillary thyroid carcinoma**

3 Dingcun Luo^{1*,#}, Yeqin Ni^{2*}, Shirong Zhang^{3,#}, Yanping Xun³, Pan Zhao⁴, Fan
4 Wu², Tianhan Zhou², Jingjing Shi¹, Si Lu⁵, Sihan Sun⁶, Kaining Lu⁶

5 ¹Department of Surgical Oncology, Affiliated Hangzhou First People's Hospital,
6 Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang, China

7 ²Zhejiang Chinese Medical University, The Fourth Clinical College, Hangzhou
8 310006, Zhejiang, China

9 ³Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital,
10 Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang, China

11 ⁴Department of Pathology, Affiliated Hangzhou First People's Hospital,
12 Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang, China

13 ⁵Institute of Translational Medicine, Zhejiang University School of Medicine,
14 Hangzhou 310058, Zhejiang, China

15 ⁶Nanjing Medical University, Nanjing 211166, Jiangsu, China

16 *These authors contributed equally to this work

17

18 **#Corresponding authors**

19 Dingcun Luo, B.M

20 Department of Surgical Oncology, Affiliated Hangzhou First People's Hospital,
21 Zhejiang University School of Medicine

22 No. 261, Huansha Road, Shangcheng district, Hangzhou 310006

23 P. R. China

24 E-mail: ldc65@163.com

25 Shirong Zhang, M.D, Ph.D

26 Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital,
27 Zhejiang University School of Medicine

28 No. 261, Huansha Road, Shangcheng district, Hangzhou 310006

29 P. R. China

30 E-mail: shirleyz4444@163.com

31

32

33 **ABSTRACT**

34 **Background** The BRAFV600E mutations is an important molecular event in
35 the occurrence and development of papillary thyroid carcinoma (PTC). A
36 qualitative detection of the BRAFV600E mutation is still insufficient to explain
37 the biological behavior of PTC. Though quantitative detection of the
38 BRAFV600E mutation can reflect certain characteristics of PTC, its clinical
39 value is still controversial. We aimed to investigate the association between
40 the ratio of BRAFV600E alleles and clinicopathological parameters in PTC
41 patients.

42 **Methods** Genomic DNA was extracted from specimens obtained from 329
43 PTC patients undergoing thyroidectomy. The ratio of BRAFV600E alleles was
44 determined by amplification refractory mutation system (ARMS) and droplet
45 digital polymerase chain reaction (ddPCR). Inconsistent results were further
46 verified by next-generation sequencing (NGS). The clinicopathologic features,
47 clinical tumor stage, and tumor recurrence risk stratification of all patients were
48 correlated with the ratio of BRAFV600E alleles.

49 **Results** The sensitivity of ddPCR was superior to that of ARMS and almost the
50 same as that of NGS. In total, 275 of 329 patients had the BRAFV600E
51 mutation as determined by ARMS, ddPCR and NGS. The ratio of BRAFV600E
52 alleles ranged from 0.17%-48.0%, with a median ratio of 12.58%, and

53 significantly correlated with tumor size ($p < 0.001$), capsule or extrathyroidal
54 invasion ($p < 0.001$), the number or rate of lymph node metastases ($p < 0.001$),
55 tumor stage ($p = 0.006$) and tumor recurrence risk ($p < 0.001$) but not with sex,
56 age or multifocality. The ratio of BRAFV600E alleles was much lower in PTC
57 patients with Hashimoto's thyroiditis than in those without ($p < 0.001$).

58 **Conclusions** The ratio of BRAFV600E alleles can reliably reflect the biological
59 behavior of PTC, making it a molecular-based stratification index of recurrence
60 risk. The quantitative detection of BRAFV600E has the potential to guide the
61 clinical diagnosis and treatment of PTC.

62 **Keywords:** papillary thyroid carcinoma, BRAF, droplet digital PCR,
63 quantification, biological behavior

64

65 INTRODUCTION

66 Papillary thyroid carcinoma (PTC) is the most common malignant tumor in
67 the endocrine system, and its incidence has rapidly increased in the past
68 decade(1). Although most PTCs progress slowly, with a high survival rate and
69 a low recurrence rate, some patients are very prone to cervical lymph node
70 metastasis (LNM) and distant metastasis and even die of persistent or
71 recurrent disease that is refractory to conventional therapies(2-4). Large-scale
72 multicenter studies have demonstrated an association between BRAFV600E

73 and PTC prognosis as well as PTC-specific mortality(5). Data from
74 meta-analyses have consistently indicated that the presence of the
75 BRAFV600E mutation in PTC is associated with extrathyroidal invasion, lymph
76 node metastasis, advanced TNM stage, and tumor recurrence(6-9).
77 Interestingly, PTCs with aggressive biological behaviors, such as those with
78 the BRAFV600E mutation, can occur in small tumors, and thyroid
79 microcarcinomas with the BRAFV600E mutation are frequently associated with
80 extrathyroidal extension and lymph node metastasis(10).

81 BRAF is a cytoplasmic serine-threonine protein kinase. Among the three
82 forms of RAF kinases, BRAF is the most potent activator of the mitogen
83 activated protein kinase (MAPK) pathway. The vast majority of BRAF allele
84 alterations are characterized by a single amino acid substitution of valine by
85 glutamic acid in a mutational hotspot at amino acid position 600 (BRAF
86 c.1799T>A (p.Val600Glu), referred to hereafter as BRAFV600E(11-13). The
87 BRAFV600E mutation is a negative prognostic marker in PTC.

88 With the development of detection techniques including
89 amplification refractory mutation system (ARMS) and next-generation
90 sequencing (NGS), the BRAFV600E mutation can be found in approximately
91 79%-87% of PTC patients, and it is an important molecular marker for PTC
92 diagnosis, treatment and prognosis(12-18). The significance of the

93 BRAFV600E mutation in the qualitative diagnosis of thyroid nodules is
94 increasing, but the association between the BRAFV600E mutation and
95 clinicopathological features and its impact on clinical outcomes remain
96 challenging or unclear in PTC, especially in patients with microcarcinoma(19,
97 20). Guerra et al. demonstrated that completely clonal PTC harboring the
98 BRAFV600E mutation was rare and that PTC was frequently associated with a
99 mixture of wild-type and mutant BRAF alleles. The association between the
100 BRAFV600E mutation and the clinicopathological features of PTC should be
101 reevaluated, taking into account the fraction of mutant BRAF alleles(21, 22).
102 We speculated that the larger the proportion of mutated BRAF alleles detected,
103 the more aggressive the tumor. Therefore, the quantitative detection of
104 BRAFV600E alleles should help clarify the relationship between the
105 BRAFV600E mutation and the clinical behavior of PTC patients.

106 Droplet digital PCR (ddPCR) is a novel technology that provides sensitive
107 and absolute nucleic acid quantification. It is far more sensitive and specific
108 than other methods because of amplification at the nanoliter level and can
109 accurately measure trace amounts of nucleic acids. Detection of the
110 BRAFV600E mutation by ddPCR has been demonstrated in melanoma
111 samples and pancreas fine needle aspiration (FNA) specimens(23-25). A
112 recent study showed that mutant BRAFV600E was detected in 56%(42/75) of
113 PTC tumors by ddPCR and that the ratio of mutant/total BRAF alleles varied

114 from 4.7% to 47.5%, suggesting that ddPCR detection of the BRAFV600E
115 mutation should be a suitable assay for the molecular-based stratification of
116 prognosis in patients with PTC(26).

117 According to the 2015 American Thyroid Association (ATA) Management
118 Guidelines for Differentiated Thyroid Cancer on the risk stratification of PTC
119 recurrence(27), in this study, we investigated a correlation between the ratio of
120 BRAFV600E alleles and disease risk (high, intermediate and low). We aimed
121 to provide a reliable and molecular-based risk stratification for PTC patients.
122 To this end, we used ddPCR and ARMS to detect the ratio of BRAFV600E
123 alleles in PTC tissues and paracancerous tissues. If the results of ddPCR and
124 ARMS were inconsistent, NGS was used for further clarification.

125

126 **MATERIALS AND METHODS**

127 **Patients and sample correction**

128 A total of 329 PTC patients who visited Affiliated Hangzhou First People's
129 Hospital, Zhejiang University School of Medicine between 2016 and 2018, and
130 their matched formalin-fixed paraffin-embedded (FFPE) blocks were randomly
131 and consecutively selected and analyzed for the BRAFV600E mutation. The
132 exclusion criteria were as follows: (1) patients who had a history of treatments
133 for thyroid cancer, (2) patients with other cervical malignant tumors, and (3)

134 patients with both thyroid cancer and Graves' disease or other endocrine
135 disorder. Fresh tumor tissues and their paracancerous tissues were carefully
136 dissected during the operation in 10 of 329 PTC patients. PTC tissues were
137 collected from the center of the tumor lesions, and paracancerous tissues were
138 obtained at least 2 cm from the margins of the tumor lesions. Histological
139 diagnoses were established according to the WHO classification after the
140 examination of hematoxylin and eosin-stained slides. The pathological
141 diagnosis was performed by two thyroid pathologists. If there were different
142 opinions, a third expert participated in the diagnosis, and the opinions of the
143 two experts were used as the final diagnosis. A total of 144 PTC patients
144 underwent total thyroidectomy, and 185 underwent hemithyroidectomy. All
145 patients underwent neck central compartment lymph node dissection.
146 Fifty-seven patients underwent therapeutic neck lateral compartment lymph
147 node dissection. In this study, we extracted the following clinicopathologic
148 variables: sex, age, multifocality, tumor diameter, capsule invasion,
149 extrathyroid extension, Hashimoto's thyroiditis (HT) and lymph node
150 metastasis. Each patient was classified according to the 8th revision of the
151 TNM staging system by the American Joint Committee on Cancer(AJCC)(28).
152 The diagnostic criteria of Hashimoto's thyroiditis were based on pathology or
153 serum thyroid globulin antibody and peroxidase antibody combined with
154 ultrasound characteristics(29,30). According to the risk of structural disease

155 recurrence offered by the 2015 ATA Management Guidelines for Differentiated
156 Thyroid Cancer, all patients were stratified as low, intermediate and high
157 risk(27). All patients were followed up for a period of 16-50 months. One
158 patient died of lung metastasis, and another patient developed recurrent
159 cervical lymph node metastases. The remaining patients survived without
160 recurrence. This study was approved by the Institutional Ethics Committee of
161 Affiliated Hangzhou First People's Hospital, Zhejiang University School of
162 Medicine. All patients provided informed consent, and they all agreed to
163 participate in this study. All procedures were performed in accordance with the
164 Declaration of Helsinki.

165 **DNA extraction**

166 The extraction of DNA from fresh frozen thyroid tissue was performed
167 using a QIAamp DNA Mini Kit (QIAGEN Inc., Hilden), following the
168 manufacturer's instructions. The FFPE blocks of PTC samples were
169 deparaffinized with xylene and rehydrated through ethanol (100%). Then, the
170 extraction of DNA was performed using a QIAamp DNA FFPE Tissue Kit
171 (QIAGEN Inc., Hilden) according to the manufacturer's instructions. DNA
172 quantification was performed on a NanoDrop 1000 (Thermo Fisher Inc.,
173 Waltham) according to the manufacturer's instructions. The DNA had a purity
174 $1.8 \leq A_{260}/A_{280} \leq 2.0$ and a concentration greater than 10.0 mg/L.

175 **ddPCR**

176 ddPCR was performed on a QX-200 Droplet Digital PCR System (Bio-Rad
177 Inc., Hercules). The primer and probe for detection of the BRAFV600E
178 mutation were purchased from Bio-Rad. Two probes with one nucleotide
179 difference that target the mutated region were labeled with carboxyfluorescein
180 (FAM) and green fluorescent protein (VIC) dyes to detect mutant and wild-type
181 BRAFV600E alleles, respectively. The final TaqMan PCR mixture (20 μ L)
182 containing 50 ng of template DNA was prepared. The thermal cycling
183 conditions for the BRAFV600E detection assay comprised a 10-min incubation
184 at 95 °C followed by 40 cycles at 94 °C for 15 s and 58 °C for 1 min, followed
185 by a hold step at 4 °C for 5min. The analyses of ddPCR data for allele calling
186 was performed with Quanta Soft software version 1.3.2.0 (Bio-Rad). All
187 experiments and data analysis were performed according to the
188 manufacturer's instructions (YuanQi BioTech, China). Considering that single,
189 nonspecific droplets were occasionally found in the positive area, the presence
190 of at least three droplets with the FAM signal was defined as positive signal for
191 the mutation. The ratio of BRAFV600E mutations was calculated with the
192 following equation: (FAM positive droplet + FAM/VIC dual positive
193 droplet)/(FAM positive droplet + VIC positive droplet + FAM/VIC dual positive
194 droplet). The threshold was set at 0.1% of the ratio, as described in the
195 manufacturer's instructions.

196 **ARMS**

197 ARMS was performed using an ABI 7500 system (Thermo Fisher Inc.,
198 Waltham). The ARMS kit for BRAFV600E mutation detection was purchased
199 from AccBio Inc. (Beijing). The final PCR mixture (45 μ L) was amplified under
200 the following conditions: 1 cycle at 95 °C for 5 min; 15 cycles at 95 °C for 25 s
201 and 64 °C for 20 s, followed by 72 °C for 20 s; and 31 cycles at 93 °C for 25 s,
202 60 °C for 35 s and 72 °C for 20 s. The FAM signals were detected at 60 °C. The
203 definition of BRAFV600E status was classified by the FAM cycle threshold(Ct)
204 value: (1) if the Ct value was <35, the sample was defined as positive; (2) if the
205 Ct value was between 35-38, the sample was defined as suspicious; and (3) if
206 the Ct value was >38, the sample was defined as negative.

207 **NGS**

208 Due to the inconsistent results produced by ddPCR and ARMS, 16 of 329
209 specimens were analyzed with an AmpliSeq Cancer Hotspot Panel (v2) (Life
210 Technologies Inc., Carlsbad) as described previously(31). BRAFV600E
211 sequencing data were analyzed using Torrent Suite (Life Technologies Inc.,
212 Carlsbad). Mutations were identified and annotated through both Torrent
213 Variant Caller and a direct visual inspection of the binary sequence
214 alignment/map (BAM) file on the Broad Institute's Integrative Genomics Viewer
215 (IGV) (32).

216 **Normalization of BRAFV600E alleles to the proportion of neoplastic cells**

217 The ratio of BRAFV600E alleles obtained by ddPCR was normalized to the
218 proportion of neoplastic cells (vs contaminant cells, such as inflammatory or
219 stromal cells) in each sample using the following formula: (normalized ratio of
220 BRAFV600E alleles = ratio of BRAFV600E alleles / proportion of neoplastic
221 cells). The proportion of neoplastic cells was calculated as a percentage after a
222 careful microscopic evaluation of the tumor area on the hematoxylin and
223 eosin-stained slide by two pathologists separately.

224 **Statistical Analysis**

225 Medians with interquartile ranges were calculated for continuous variables,
226 and numbers and percentages were calculated for categorical variables.
227 Normality was tested with Kolmogorov-Smirnov tests. The Mann-Whitney *U*
228 test was used to compare continuous, nonnormally distributed variables. The
229 Kruskal-Wallis H test was used to compare variables between more than two
230 groups. Pearson's chi-square test or Fisher's exact test was used to compare
231 categorical variables. The Spearman rank-correlation test was used to analyze
232 the correlation between two continuous variables. All statistical analyses were
233 performed with SPSS statistical software (version 25.0). A *P* value<0.05 was
234 considered statistically significant.

235

236 **Results**

237 **Detection of the BRAFV600E mutation by ddPCR, ARMS and NGS**

238 Among the 329 patients, 274 (83.28%) were detected the BRAFV600E
239 mutation by ddPCR, and 263 (79.94%) were found to have the BRAFV600E
240 mutation by ARMS. There was no significant difference between the data
241 obtained from the two methods ($p=0.268$, Table 1). The ARMS and ddPCR
242 results were inconsistent for 16 patients; therefore, NGS was conducted. The
243 results obtained from NGS were consistent with those obtained from ddPCR for
244 15 patients and with those obtained from ARMS for one patient (Supplemental
245 table 1). Consistent results between the two methods were considered the final
246 result, revealing that 275 of 329 patients had the BRAFV600E mutation
247 (83.58%).

248 In 274 of 275 patients with the BRAFV600E mutation as determined by
249 ddPCR, the ratio of BRAFV600E alleles varied from 0.17% to 48.0% (mean
250 15.79%), the quartiles were 6.3% and 22.71% (median 12.58%). If the ratios of
251 BRAFV600E alleles obtained by ddPCR were divided into three groups, >10%,
252 1-10%, and <1%, the positive rates of BRAFV600E mutations detected by
253 ARMS were 98.1%, 94.1%, and 69.2%, respectively (Figure 1). Although there
254 was no statistically significant difference in the sensitivity of ddPCR versus that
255 of ARMS, the sensitivity of BRAFV600E mutation detection by ddPCR was

256 notably higher than that of ARMS. Additionally, analysis by ddPCR indicated
257 that there was a difference in the average ratio of BRAFV600E alleles between
258 10 fresh frozen tissues and 10 FFPE-matched specimens (30.40% vs. 23.00%).
259 However, paraffin tissues were utilized uniformly for analysis in the present
260 study because of the statistically nonsignificant difference ($P=0.302$). No
261 BRAFV600E mutation was found in 10 thyroid paracancerous tissue
262 specimens.

263 **Detection of the BRAFV600E mutation in PTC by ddPCR**

264 **Relationship between the ratio of BRAFV600E alleles and** 265 **clinicopathological features of PTC**

266 First, we analyzed the relationship between the BRAFV600E mutation
267 status and clinicopathological features of PTC patients (Table 2). Second, we
268 determined the relationship between the ratio of BRAFV600E alleles and
269 clinicopathological features (Table 3). We found that the clinicopathological
270 features of PTC patients were not closely related to the BRAFV600E mutation
271 status (Table 2) but were closely correlated to the ratio of BRAFV600E alleles
272 (Table 3). The ratio of BRAFV600E alleles was significantly associated with
273 tumor size, capsule invasion/extrathyroidal extension, LNM, TNM stage, HT,
274 and ATA recurrence risk. Sex, age and multifocality were independent of the
275 ratio of BRAFV600E alleles.

276 **Relationship between the ratio of BRAFV600E alleles and maximal tumor**
277 **diameter**

278 In our cohort, the maximal tumor diameter ranged from 2 mm to 55 mm,
279 with a median diameter of 8 mm. Patient samples were classified into three
280 groups according to the maximal tumor diameter, ≤ 10 mm, 11-20 mm, and >20
281 mm, and their median ratios of BRAFV600E alleles were 8.13%, 20.29% and
282 32.67%, respectively. The ratio of BRAFV600E alleles was significantly
283 different between these three groups ($p < 0.001$) (Table 3). It appeared that
284 there was a positive correlation between the ratio of BRAFV600E alleles and
285 maximal tumor diameter (Figure 2). Thus, the ratio of BRAFV600E alleles
286 increased with increasing maximal tumor diameter (Spearman's $\rho = 0.413$,
287 $p < 0.0001$; $R^2 = 0.189$, $p < 0.0001$).

288 **Relationship between the BRAFV600E allele ratio and**
289 **capsule/extrathyroidal invasion**

290 The median ratios of BRAFV600E alleles in 329 patients with and without
291 thyroid capsule/extrathyroidal invasion were 15.20% and 7.64%, respectively.
292 The ratios of BRAFV600E alleles were significantly different between these two
293 groups of patients ($p < 0.001$, Figure 3).

294 **Relationship between the BRAFV600E allele ratio and lymph node**
295 **metastasis**

296 A total of 154 patients had LNM, and 175 did not involve metastasis in our
297 study. Among the patients with LNM, 71 were defined as having low-volume
298 lymph node metastasis, with ≤ 5 pathologic metastatic lymph nodes and foci < 2
299 mm in the largest dimension, and 81 were defined as having high-volume
300 lymph node metastasis, with > 5 pathologic metastatic lymph nodes or foci ≥ 2
301 mm in the largest dimension. The median ratios of BRAFV600E alleles were
302 8.00% , 10.33% and 17.17%, respectively, in patients with no, low-volume and
303 high-volume lymph node metastasis. The difference between these three
304 groups was significant ($p < 0.001$, Table 3). The ratio of BRAFV600E alleles was
305 positively correlated with the number of metastatic lymph nodes (Spearman's
306 $\rho = 0.220$, $p < 0.0001$; $R^2 = 0.070$, $p < 0.0001$, Figure 4) and the rate of lymph
307 node metastasis (metastatic/dissected lymph nodes) (Spearman's $\rho = 0.232$,
308 $p < 0.0001$; $R^2 = 0.058$, $p < 0.0001$, Figures 5).

309 **Relationship between the BRAFV600E allele ratio and Hashimoto's**
310 **thyroiditis**

311 Eighty-seven PTC cases had accompanying HT. The median ratios of
312 BRAFV600E alleles in PTC patients with and without HT were 5.38% and
313 12.64%, respectively, with a significant difference ($p < 0.001$, Table 3, Figure 6).
314 HT was most frequently observed in patients with stage I PTC than those with
315 other stages of PTC. It was also noted that stage I PTC was associated with a

316 low BRAFV600E mutation ratio (Table 4), suggesting that HT may has a
317 negative impact on the BRAFV600E mutation in PTC.

318 **Relationship between the BRAFV600E allele ratio and tumor stage**

319 According to the 8th revision of the TNM staging system by the AJCC, there
320 were 282 patients with stage I disease, 40 patients with stage II disease, and 7
321 patients with stage III or IV disease among all 329 patients, and their median
322 ratios of the BRAFV600E alleles were 8.90%, 14.20% and 29.00%,
323 respectively, with significant differences($p=0.006$). We found that the
324 BRAFV600E mutation ratio increased as the tumor advanced from stage I to
325 stage IV (Table 3).

326 **Relationship between the BRAFV600E allele ratio and tumor recurrence** 327 **risk**

328 We analyzed the postoperative clinicopathological characteristics of all
329 PTC patients according to the 2015 ATA guidelines for the risk stratification
330 standard of thyroid cancer recurrence. As a result, 169 patients were
331 considered low risk, 140 were considered intermediate risk, and 20 were
332 considered high risk. The median ratios of the BRAFV600E alleles were 7.33%,
333 12.87% and 16.55% for low-, intermediate- and high-risk patients, respectively,
334 with a significant difference ($p<0.001$). Moreover, the ratio of the BRAFV600E
335 alleles increased as the risk of tumor recurrence increased (Table 3).

336

337 **DISCUSSION**

338 Although the BRAFV600E mutation has been linked to the occurrence and
339 development of PTC and associated with its clinicopathological characteristics
340 since 2003, the results are still debatable. Several factors contribute to the
341 inconsistent data. First, the different detection methods used can result in wide
342 variations in the rate of BRAF mutations found in PTC. For example, the
343 positive rate of BRAFV600E detected by NGS in PTC is usually over 80%(33),
344 whereas that detected by Sanger sequencing is approximately 45-59%(34).
345 Currently, most studies use a qualitative analysis rather than a quantitative
346 analysis of BRAFV600E mutations. Second, the difference in the number of
347 cases analyzed may lead to various outcomes. Gandolfi et al studied 132 cases
348 of PTC and concluded that the occurrence and percentage of the BRAFV600E
349 mutated allele did not have an obvious role in the development of PTC
350 metastases and that the average mutated allele percentage decreased as PTC
351 progressed from the primary location to sites of lymph node metastasis(35).
352 Thus, their results suggest that the less frequent the BRAFV600E mutation is,
353 the more aggressive the tumor, which opposes the common concept of the
354 pathologic function of BRAFV600E in PTC(36,37). It is generally believed that
355 results from a small number of cases are not reliable. Third, the difference may

356 be caused by the analysis of different clinicopathological indexes. Previous
357 studies included the tall cell and follicular subtypes with traditional PTC and
358 found that BRAFV600E mutations were exactly related to tumor
359 aggressiveness. However, if nontraditional PTC was excluded, no correlation
360 was found(34,38,39). Therefore, unified, traditional PTC must be included to
361 assess its correlation with BRAFV600E mutations. Finally, different disease
362 stages may also contribute to the variation. For example, Gan et al. reported
363 that BRAFV600E was closely associated with the clinicopathological
364 characteristics of patients with stage II or above PTC, but such an association
365 was not observed in patients with stage I PTC(40). Therefore, the difference in
366 the proportion of PTC patients in different tumor stages may also contribute to
367 the variation. In this study, we employed the most updated detection
368 technology to quantitatively analyze BRAFV600E mutations in 329 patients
369 with traditional PTC. To the best of our knowledge, this is the largest number of
370 PTC cases studied so far. We selected a total of 11 clinicopathological
371 characteristics for the analysis, the most comprehensive and greatest number
372 of indexes analyzed thus far.

373 This study found that the sensitivity of ddPCR to detect BRAFV600E
374 mutations in PTC was almost equal to that of NGS, and higher than that of
375 ARMS (Table1). The BRAFV600E mutation was undetectable by ARMS but
376 detectable by ddPCR in 13 patients. Among the 329 PTC patients, the ratio of

377 BRAFV600E alleles in 165 cases was less than 10%, which is usually beyond
378 the range detected by the first-generation gene detection technology(26,41).

379 The aggressiveness of PTC is usually determined by tumor size, capsule
380 and extrathyroidal invasion, LNM, and pulmonary and bone metastasis. These
381 clinicopathological features of PTC can directly indicate the tumor stage and
382 objectively reflect the risk of tumor recurrence. These indexes have been
383 consistently recognized and used to guide the clinical diagnosis and treatment
384 of PTC. In our study, the BRAFV600E allele ratio but not the BRAFV600E
385 mutation in PTC tissues was positively correlated with these features.
386 Therefore, the aggressiveness of PTC can be reliably assessed by the
387 quantitative index of the BRAF600E allele ratio, making the BRAFV600E allele
388 ratio a molecular marker for the clinical evaluation of PTC aggressiveness.

389 The detection of the BRAFV600E allele ratio can be influenced by the
390 coexistence of other pathologic conditions in the thyroid. The study by Colombo
391 et al indicated that some wild-type BRAF alleles detected in PTC were in fact
392 from inflammatory or stromal cells, regarded as “contamination”(42).
393 Accordingly, the frequency of mutated alleles must be normalized to the
394 percentage of neoplastic cells in the samples(43). After the exclusion of
395 contamination, we found significant differences in the BRAFV600E mutation
396 ratio in the whole group of PTC, which presented different biological behaviors

397 and clinical characteristics.

398 It is well known that a proportion of PTC can coexist with or develop from
399 HT, an autoimmune disease. In this study, we stratified PTC patients with or
400 without HT and found that PTC patients with HT had a lower BRAFV600E allele
401 ratio than those without. Moreover, the proportion of stage I PTC patients with
402 HT was significantly higher than that of those without (Table 4). These
403 observations are supported by the fact that the lymphocytic infiltration of HT is a
404 protective factor against PTC progression(44). This clinical phenomenon can
405 also be explained by another finding in our study: PTC patients with HT carried
406 fewer BRAFV600E mutations are likely to be less aggressive. However, the
407 mechanism responsible is unclear. It is possible that inflammation in the thyroid
408 may prevent the occurrence of BRAFV600E mutations or have a negative
409 impact on BRAFV600E mutations.

410 The risk stratification of PTC recurrence recommended by the ATA in 2015
411 has important clinical guiding value for postoperative iodine-131 treatment and
412 follow-up(27). In our study, the median ratio of BRAFV600E alleles in low-,
413 intermediate- and high-risk patients was 7.33%, 12.87%, 16.55%, respectively,
414 with a significant difference ($p < 0.001$). It was noted that the size of the tumor
415 may not always be positively correlated with the ratio of BRAFV600E alleles.
416 For example, in the high-risk group, the tumor diameter of some patients was

417 only 6 mm, but the BRAFV600E allele ratio was up to 14.3%. However, in the
418 low-risk group, the tumor diameter of some patients reached 12 mm, while the
419 BRAFV600E allele ratio was only 0.2%. Therefore, it is more accurate or
420 meaningful to evaluate the risk of recurrence of PTC by quantitatively detecting
421 the BRAF allele ratio rather than measuring the tumor diameter. Furthermore, if
422 quantitative detection of the BRAF allele ratio is applied in a sample obtained
423 from preoperative FNA, this concept and technique will provide important
424 guidance for decisions regarding the management of PTC, including the pattern
425 of thyroidectomy and cervical lymph node dissection.

426 Several limitations to this study should be acknowledged. First, in this study,
427 83.58% of PTC patients had the BRAFV600E mutation, and 16.42% did not,
428 indicating that the BRAFV600E mutation is not the only factor contributing to
429 the occurrence and development of PTC. Though the BRAFV600E mutation is
430 the most frequent genetic event found in PTC, other genetic changes such as
431 TERT, KRAS and HRAS mutations, RET fusions, and TRK rearrangements
432 have also been reported(42,45). Therefore, an accurate risk stratification of
433 PTC requires not only a mutation analysis of a single genetic event, but also a
434 comprehensive analysis of other types of genetic alterations. Second, parts of
435 the tumor tissues subjected to genetic testing and staining may not be matched
436 exactly. Third, since intratumor heterogeneity is objective, tumor tissues
437 subjected to mutation detection may not be representative of the whole

438 tumor(46). To the best of our knowledge, the sample number we examined was
439 the largest so far, but selection bias, which affects the detection results, cannot
440 be excluded. Finally, our work is a single-center retrospective study, and a
441 multicenter prospective study is required to further evaluate the prognostic
442 significance of the ratio of BRAFV600E alleles in PTC.

443

444 **CONCLUSIONS**

445 ddPCR can accurately and quantitatively detect the BRAFV600E allele
446 ratio in PTC. The BRAFV600E allele ratio is closely related to the clinical
447 aggressiveness of PTC and can reflect the biological behavior of PTC.
448 Therefore, it can be used as a molecular-based stratification index of
449 recurrence risk and should aid in decisions regarding the clinical diagnosis and
450 treatment of PTC.

451

452 **ACKNOWLEDGMENTS**

453 This work was supported by grant from the Key Project of Scientific and
454 Technological Innovation in Hangzhou (award number: 20131813A08) and the
455 Medical Science Research Program of Hangzhou (award number:
456 OO20190490). The authors are grateful to all members of the Department of

457 Surgical Oncology, Centre of Translational Medicine, and Department of
458 Pathology at Hangzhou First People's Hospital.

459 **AUTHORS CONTRIBUTIONS**

460 DC.L and YQ.N designed the study and wrote the paper. YP.X, P.Z, JJ.S and
461 S.L analyzed the data and performed the study. F.W, TH.Z, SH.S and KN.L
462 contributed with data collection and patients follow-up. DC.L and SR.Z
463 supervised the whole process and critically revised the paper. All authors read
464 and approved the final version.

465 **AUTHOR DISCLOSURE STATEMENT**

466 The authors declare that there are no conflicts of interest.

467

468 **REFERENCES**

- 469 **1.** Siegel RL, Miller KD, Jemal A 2019 Cancer statistics, 2019. CA: a
470 cancer journal for clinicians **69**:7-34.
- 471 **2.** Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA,
472 Smit JW 2006 Survival and death causes in differentiated thyroid
473 carcinoma. J Clin Endocrinol Metab **91**:313-319.
- 474 **3.** Jarzab B, Dedecjus M, Handkiewicz-Junak D, Lange D, Lewiński A,
475 Nasierowska-Guttmejer A, Ruchała M, Słowińska-Klencka D, Nauman J,
476 Adamczewski Z, Bagłaj M, Bałdys-Waligórska A, Barczyński M,
477 Bednarczuk T, Cichocki A, Czarniecka A, Czepczyński R, Gawlik A,
478 Hubalewska-Dydejczyk A, Jażdżewski K, Kamiński G,
479 Karbownik-Lewińska M, Kos-Kudła B, Kułakowski A, Kuzdak K, Łącka
480 K, Małecka-Tendera E, Niedziela M, Pomorski L, Sporny S, Stojcev Z,
481 Syrenicz A, Włoch J, Krajewska J, Szpak-Ulczoek S, Kalemba M,
482 Buziak-Bereza M 2016 Diagnostics and Treatment of Thyroid
483 Carcinoma. Endokrynol Pol **67**:74-107.
- 484 **4.** Jarzab B, Dedecjus M, Słowińska-Klencka D, Lewiński A, Adamczewski
485 Z, Anielski R, Bagłaj M, Bałdys-Waligórska A, Barczyński M,
486 Bednarczuk T, Bossowski A, Buziak-Bereza M, Chmielik E, Cichocki A,
487 Czarniecka A, Czepczyński R, Dzięcioł J, Gawlik T, Handkiewicz-Junak

- 488 D, Hasse-Lazar K, Hubalewska-Dydejczyk A, Jażdżewski K,
489 Jurecka-Lubieniecka B, Kalemba M, Kamiński G, Karbownik-Lewińska
490 M, Klencki M, Kos-Kudła B, Kotecka-Blicharz A, Kowalska A, Krajewska
491 J, Kropińska A, Kukulska A, Kulik E, Kułakowski A, Kuzdak K, Lange D,
492 Ledwon A, Lewandowska-Jabłońska E, Łącka K, Michalik B,
493 Nasierowska-Guttmejer A, Nauman J, Niedziela M, Małecka-Tendera E,
494 Oczko-Wojciechowska M, Olczyk T, Paliczka-Cieślik E, Pomorski L,
495 Puch Z, Roskosz J, Ruchała M, Rusinek D, Sporny S, Stanek-Widera A,
496 Stojcev Z, Syguła A, Syrenicz A, Szpak-Ulczoek S, Tomkalski T, Wygoda
497 Z, Włoch J, Zembala-Nożyńska E 2018 Guidelines of Polish National
498 Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018
499 Update. *Endokrynol Pol* **69**:34-74.
- 500 **5.** Xing M 2013 BRAF V600E mutation and papillary thyroid cancer. *JAMA*
501 **310**:535.
- 502 **6.** Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK,
503 Youn YK, Kim KH, Cho BY, Park DJ 2012 The association of the
504 BRAF(V600E) mutation with prognostic factors and poor clinical
505 outcome in papillary thyroid cancer: a meta-analysis. *Cancer*
506 **118**:1764-1773.
- 507 **7.** Li C, Lee KC, Schneider EB, Zeiger MA 2012 BRAF V600E mutation

- 508 and its association with clinicopathological features of papillary thyroid
509 cancer: a meta-analysis. *J Clin Endocrinol Metab* **97**:4559-4570.
- 510 **8.** Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M 2012 BRAF
511 mutation in papillary thyroid cancer and its value in tailoring initial
512 treatment: a systematic review and meta-analysis. *Medicine (Baltimore)*
513 **91**:274-286.
- 514 **9.** Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role,
515 molecular bases, and clinical implications. *Endocr Rev* **28**:742-762.
- 516 **10.** Lin K, Wang O, Zhang X, Dai X, Hu X, Qu J 2010 The BRAF mutation is
517 predictive of aggressive clinicopathological characteristics in papillary
518 thyroid microcarcinoma. *Ann Surg Oncol* **17**:3294-3300.
- 519 **11.** Mercer K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M,
520 Marais R, Pritchard C 2005 Expression of endogenous oncogenic
521 V600E-B-raf induces proliferation and developmental defects in mice
522 and transformation of primary fibroblasts. *Cancer Res* **65**:11493-11500.
- 523 **12.** Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM,
524 Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R 2004
525 Mechanism of activation of the RAF-ERK signaling pathway by
526 oncogenic mutations of B-RAF. *Cell* **116**:855-867.

- 527 **13.** Sithanandam G, Kolch W, Duh FM, Rapp UR 1990 Complete coding
528 sequence of a human B-raf cDNA and detection of B-raf protein kinase
529 with isozyme specific antibodies. *Oncogene* **5**:1775-1780.
- 530 **14.** Arcila M, Lau C, Nafa K, Ladanyi M 2011 Detection of KRAS and BRAF
531 mutations in colorectal carcinoma roles for high-sensitivity locked
532 nucleic acid-PCR sequencing and broad-spectrum mass spectrometry
533 genotyping. *J Mol Diagn* **13**:64-73.
- 534 **15.** Lamy PJ, Castan F, Lozano N, Montélon C, Audran P, Bibeau F,
535 Roques S, Montels F, Laberrenne AC 2015 Next-Generation Genotyping
536 by Digital PCR to Detect and Quantify the BRAF V600E Mutation in
537 Melanoma Biopsies. *J Mol Diagn* **17**:366-373.
- 538 **16.** Omholt K, Platz A, Kanter L, Ringborg U, Hansson J 2003 NRAS and
539 BRAF mutations arise early during melanoma pathogenesis and are
540 preserved throughout tumor progression. *Clin Cancer Res*
541 **9**:6483-6488.
- 542 **17.** Li X, Li E, Du J, Wang J, Zheng B 2019 BRAF mutation analysis by
543 ARMS-PCR refines thyroid nodule management. *Clin Endocrinol (Oxf)*
544 **91**:834-841.
- 545 **18.** Ren H, Shen Y, Hu D, He W, Zhou J, Cao Y, Mao Y, Xiong W,
546 Xiao Q, Zhang Y, Su X 2018 Co-existence of BRAF(V600E) and TERT

547 promoter mutations in papillary thyroid carcinoma is associated with
548 tumor aggressiveness, but not with lymph node metastasis. *Cancer*
549 *Manag Res* **10**:1005-1013.

550 **19.** George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY,
551 Clayman GL 2015 Association of TERT Promoter Mutation, But Not
552 BRAF Mutation, With Increased Mortality in PTC. *J Clin Endocrinol*
553 *Metab* **100**: E1550-E1559.

554 **20.** Zheng X, Peng C, Gao M, Zhi J, Hou X, Zhao J, Wei X, Chi J, Li D, Qian
555 B 2019 Risk factors for cervical lymph node metastasis in papillary
556 thyroid microcarcinoma: a study of 1,587 patients. *Cancer Biol Med*
557 **16**:121-130.

558 **21.** Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I,
559 Moccia T, Budillon A, Vitale M 2012 A high percentage of BRAFV600E
560 alleles in papillary thyroid carcinoma predicts a poorer outcome. *J Clin*
561 *Endocrinol Metab* **97**:2333-2340.

562 **22.** Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I,
563 Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M 2012 The primary
564 occurrence of BRAFV600E is a rare clonal event in papillary thyroid
565 carcinoma. *J Clin Endocrinol Metab* **97**:517-524.

566 **23.** Reid AL, Freeman JB, Millward M, Ziman M, Gray ES 2015 Detection of

567 BRAF-V600E and V600K in melanoma circulating tumour cells by
568 droplet digital PCR. Clin Biochem **48**:999-1002.

569 **24.** Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Zárata R,
570 Lozano MD, Zubiri L, Perez-Gracia JL, Martín-Algarra S, González A
571 2015 Quantitative cell-free circulating BRAFV600E mutation analysis by
572 use of droplet digital PCR in the follow-up of patients with melanoma
573 being treated with BRAF inhibitors. Clin Chem **61**:297-304.

574 **25.** Sho S, Court CM, Kim S, Braxton DR, Hou S, Muthusamy VR, Watson
575 RR, Sedarat A, Tseng H-R, Tomlinson JS 2017 Digital PCR Improves
576 Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy
577 Specimens. PLoS ONE **12**:e0170897.

578 **26.** Ylli D, Patel A, Jensen K, Li ZZ, Mendonca-Torres MC, Costello J,
579 Gomes-Lima CJ, Wartofsky L, Burman KD, Vasko VV 2019 Microfluidic
580 Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT
581 Mutations in Papillary Thyroid Carcinomas. Cancers (Basel) **11**:1916.

582 **27.** Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ,
583 Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M,
584 Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L
585 2016 2015 American Thyroid Association Management Guidelines for
586 Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:

- 587 The American Thyroid Association Guidelines Task Force on Thyroid
588 Nodules and Differentiated Thyroid Cancer. *Thyroid* **26**:1-133.
- 589 **28.** Amin E, Greene F, Byrd D, Brookland R, Washington M 2017 AJCC
590 Cancer Staging Manual. 8th ed. New York: Springer International.
- 591 **29.** Endocrinology Branch Of Chinese Medical Association 2008 [Chinese
592 thyroid disease diagnosis and treatment guidelines-thyroiditis: subacute
593 thyroiditis]. *Chinese journal of internal medicine* **47**:784-785.
- 594 **30.** Guan H, de Moraes NS, Stuart J, Ahmadi S, Marqusee E, Kim MI,
595 Alexander EK 2019 Discordance of serological and sonographic
596 markers for Hashimoto's thyroiditis with gold standard histopathology.
597 *Eur J Endocrinol* **181**:539-544.
- 598 **31.** Zheng G, Lin MT, Lokhandwala PM, Beierl K, Netto GJ, Gocke CD,
599 Eshleman JR, McCarthy E, Illei PB 2016 Clinical mutational profiling of
600 bone metastases of lung and colon carcinoma and malignant
601 melanoma using next-generation sequencing. *Cancer Cytopathol*
602 **124**:744-753.
- 603 **32.** Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES,
604 Getz G, Mesirov JP 2011 Integrative genomics viewer. *Nat Biotechnol*
605 **29**:24-26.

- 606 **33.** Yu FX, Hu MX, Zhao HX, Niu LJ, Rong XY, Li WH, Zhu Q, Ying JM, Lyu
607 N 2019 Precise Detection of Gene Mutations in Fine-Needle Aspiration
608 Specimens of the Papillary Thyroid Microcarcinoma Using
609 Next-Generation Sequencing. *Int J Endocrinol* **2019**:4723958.
- 610 **34.** Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ,
611 Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P,
612 Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD,
613 Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a
614 poorer clinical prognosis for papillary thyroid cancer. *J Clin Endocrinol*
615 *Metab* **90**:6373-6379.
- 616 **35.** Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S,
617 Ciarrocchi A 2013 Allele Percentage of the BRAFV600E Mutation in
618 Papillary Thyroid Carcinomas and Corresponding Lymph Node
619 Metastases: No Evidence for a Role in Tumor Progression. *J Clin*
620 *Endocrinol Metab* **98**:E934-E942.
- 621 **36.** Kim MH, Bae JS, Lim DJ, Lee H, Jeon SR, Park GS, Jung CK 2014
622 Quantification of BRAF V600E alleles predicts papillary thyroid cancer
623 progression. *Endocr Relat Cancer* **21**:891-902.
- 624 **37.** Liu L, Chang JW, Jung SN, Park HS, Oh T, Lim YC, Koo BS 2016
625 Clinical implications of the extent of BRAFV600E alleles in patients with

- 626 papillary thyroid carcinoma. *Oral Oncol* **62**:72-77.
- 627 **38.** Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA
628 2013 Lack of association of BRAF mutation with negative prognostic
629 indicators in papillary thyroid carcinoma: the University of California,
630 San Francisco, experience. *JAMA Otolaryngol Head Neck Surg*
631 **139**:1164-1170.
- 632 **39.** Ma H, Wang R, Fang J, Zhong Q, Chen X, Hou L, Feng L, Chen X,
633 Huang Z, Zhao H 2020 A meta-analysis evaluating the relationship
634 between B-type Raf kinase mutation and cervical lymphatic metastasis
635 in papillary thyroid cancer. *Medicine (Baltimore)* **99**:e18917.
- 636 **40.** Gan X, Shen F, Deng X, Feng J, Lu J, Cai W, Peng L, Zheng W, Wang
637 W, Huang P, Chen Z, Guo M, Xu B 2020 Prognostic implications of the
638 BRAF-V600(E) mutation in papillary thyroid carcinoma based on a new
639 cut-off age stratification. *Oncol Lett* **19**:631-640.
- 640 **41.** Pesenti C, Muzza M, Colombo C, Proverbio MC, Farè C, Ferrero S,
641 Miozzo M, Fugazzola L, Tabano S 2018 MassARRAY-based
642 simultaneous detection of hotspot somatic mutations and recurrent
643 fusion genes in papillary thyroid carcinoma: the PTC-MA assay.
644 *Endocrine* **61**:36-41.
- 645 **42.** Colombo C, Muzza M, Proverbio MC, Tosi D, Soranna D, Pesenti C,

- 646 Rossi S, Cirello V, De Leo S, Fusco N, Miozzo M, Bulfamante G,
647 Vicentini L, Ferrero S, Zambon A, Tabano S, Fugazzola L 2019 Impact
648 of Mutation Density and Heterogeneity on Papillary Thyroid Cancer
649 Clinical Features and Remission Probability. *Thyroid* **29**:237-251.
- 650 **43.** Finkel A, Liba L, Simon E, Bick T, Prinz E, Sabo E, Ben-Izhak O,
651 Hershkovitz D 2016 Subclonality for BRAF mutation in papillary thyroid
652 carcinoma Is associated with earlier disease stage. *J Clin Endocrinol*
653 *Metab* **101**:1407-1413.
- 654 **44.** Marotta V, Guerra A, Zatelli MC, Uberti ED, Di Stasi V, Faggiano A,
655 Colao A, Vitale M 2013 BRAF mutation positive papillary thyroid
656 carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic
657 infiltration is present. *Clin Endocrinol (Oxf)* **79**:733-738.
- 658 **45.** Lu Z, Zhang Y, Feng D, Sheng J, Yang W, Liu B 2017 Targeted next
659 generation sequencing identifies somatic mutations and gene fusions in
660 papillary thyroid carcinoma. *Oncotarget* **8**:45784-45792.
- 661 **46.** Fugazzola L, Muzza M, Pogliaghi G, Vitale M 2020 Intratumoral genetic
662 heterogeneity in papillary thyroid cancer: occurrence and clinical
663 significance. *Cancers (Basel)* **12**: 383.

Table 1. The positive rate of BRAFV600E mutation detected by ddPCR and ARMS in PTC

	BRAF-positive	BRAF-negative	χ^2	<i>P value</i>
ddPCR	274 (83.28%)	55 (16.72%)	1.225	0.268
ARMS	263 (79.94%)	66 (20.06%)		

Table 2. The relationship between BRAFV600E mutation status and clinicopathological features in PTC patients

Clinicopathological features	Number, n(%)	BRAF-negative, n(%)	BRAF-positive, n(%)	χ^2/Z	<i>P</i> value
	329	54	275		
Gender				0.133	0.715
Female	237(72.0%)	40(74.1%)	197(71.6%)		
Male	92(28.0%)	14(25.9%)	78(28.4%)		
Age, years (median and interquartile)		49(35-55)	48(36-57)	-0.267	0.790
<55	227(69.0%)	40(74.1%)	187(68.0%)	0.778	0.378
≥55	102(31.0%)	14(25.9%)	88(32.0%)		
Multifocality				0.583	0.445
Unifocal	223(67.8%)	39(72.2%)	184(66.9%)		
Multifocal	106(32.2%)	15(27.8%)	91(33.1%)		
Tumor size		7(5-11)	8(6-12)	-1.360	0.174

(median	and					
interquartile)						
≤10	231(70.2%)	40(74.1%)	191(69.5%)	0.677	0.768	
11-20	75(22.8%)	10(18.5%)	65(23.6%)			
>20	23(7.0%)	4(7.4%)	19(6.9%)			
Capsule/extrathyro				1.027	0.311	
idal invasion						
Non-invasion	218(66.3%)	39(72.2%)	179(65.1%)			
Invasion	111(33.7%)	15(27.8%)	96(34.9%)			
Hashimoto's				6.789	0.009	
thyroiditis						
Non-combined	242(73.6%)	32(59.3%)	210(76.4%)			
combined	87(26.4%)	22(40.7%)	65(23.6%)			
Status of LNM [#]				3.615	0.169	
Non-metastasis	175(53.2%)	35(64.8%)	140(50.9%)			
Low-volume	71(21.6%)	8(14.8%)	63(22.9%)			
metastasis						

High-volume	83(25.2%)	11(20.4%)	72(26.2%)		
metastasis					
TNM stage					
I	282(85.7%)	52(96.3%)	230(83.6%)	5.617	0.052
II	40(12.2%)	2(3.7%)	38(13.8%)		
III+IV	7(2.1%)	0(0.0%)	7(2.5%)		
Risk stratification				3.543	0.161
of recurrence					
Low	169(51.4%)	34(63.0%)	135(49.1%)		
Inter	140(42.6%)	17(31.5%)	123(44.7%)		
High	20(6.0%)	3(5.6%)	17(6.2%)		

#The definition of status of lymph node metastasis:

1. Low-volume metastasis: ≤ 5 pathologic metastatic lymph nodes (foci < 2 mm in largest dimension measured under the microscopy).
2. High-volume metastasis: (1) > 5 pathologic metastatic lymph nodes; (2) metastatic lymph nodes foci ≥ 2 mm in largest dimension measured under the microscopy.

Table 3 . The relationship between the ratio of BRAFV600E alleles and clinicopathological features in PTC patients

Clinicopathological features	The ratio of BRAFV600E alleles(%), median(interquartile range)	Z/Z*	P value
Gender		-0.830	0.407
Female	9.40(2.23-20.31)		
Male	11.95(2.70-22.29)		
Age, years		-1.239	0.215
<55	8.80(1.74-21.13)		
≥55	12.19(4.55-19.70)		
Multifocality		-0.326	0.745
Unifocal	9.40(2.13-20.38)		
Multifocal	10.48(2.59-20.36)		
Tumor diameters, mm		27.574*	<0.001
≤10	8.13(1.66-15.20)		

11-20	20.29(5.38-26.25)		
>20	32.67(2.13-40.56)		
Capsule/extrathyroidal invasion		-3.735	<0.001
Non-invasion	7.64(1.61-17.47)		
Invasion	15.20(6.21-26.25)		
Hashimoto's thyroiditis		-5.236	<0.001
Non-combined	12.64(4.67-23.82)		
Combined	5.38(0.17-11.11)		
Status of LNM [#]		17.966*	<0.001
Non-metastasis	8.00(1.55-16.22)		
Low-volume metastasis	10.33(2.47-21.14)		
High-volume metastasis	17.17(6.21-30.00)		
TNM stage		10.271*	0.006
I	8.90(1.65-19.92)		

II	14.20(7.49-20.29)		
III+IV	29.00(12.00-38.00)		
Risk stratification of recurrence		17.342*	<0.001
Low	7.33(1.35-15.85)		
Inter	12.87(5.06-25.77)		
High	16.55(1.13-29.64)		

Note: **Z/Z***: Mann-Whitney *U* test /Kruskal-Wallis H test were used for continuous abnormally distributed variables.

#The definition of status of lymph node metastasis:

1. Low-volume metastasis: ≤ 5 pathologic metastatic lymph nodes (foci $< 2\text{mm}$ in largest dimension measured under the microscopy).
2. High-volume metastasis: (1) > 5 pathologic metastatic lymph nodes;(2) metastatic lymph nodes foci $\geq 2\text{mm}$ in largest dimension measured under the microscopy.

Table 4. Comparison of BRAFV600E allele ratio and tumor stage between Hashimoto's thyroiditis and those without in PTC patients

Hashimoto's thyroiditis	TNM stage, n(%)		χ^2	<i>P value</i>	The ratio of BRAFV600E alleles	<i>P value</i>
	Stage I	Stage II-III-IV				
Non-combined	201(83.1%)	41(16.9%)	5.274	0.022	12.64(4.67-23.82)	<0.001
Combined	81(93.1%)	6(6.9%)			5.38(0.17-11.11)	




Figure 1. BRAFV600E mutation analysis in tissues sampled by ddPCR and ARMS in 275 PTC patients. The red bars indicate the ratio of BRAFV600E alleles detected by ddPCR (left Y-axis), in which 0.1% used as a cut-off value to define the BRAF-positive. The gray bars indicate the cycle threshold (Ct) detected by ARMS (right Y-axis). The red-thick line and fine line represent BRAFV600E alleles at ratio 1% and 10%, respectively. The gray dotted line indicates Ct value < 35 as a threshold to define the BRAF-positive by ARMS.




Figure 2. Correlation between BRAFV600E alleles ratio and maximal tumor diameter in PTC. Note: Scatter plot shows the correlation of the ratio of BRAFV600E alleles and tumor diameter. Lines represent simple linear regression $\pm 95\%$ confidence interval. Spearman's rho = 0.413, $p < 0.0001$; simple regression adjusted $R^2 = 0.189$, $p < 0.0001$.




Figure 3. Comparison of BRAFV600E alleles ratio between capsule/extrathyroidal invasion and those without in PTC. Note: *: P value <0.001; The top of columns represents the median, and lines represent ± 95 % confidence interval.**




Figure 4. Correlation between BRAFV600E alleles ratio and the number of lymph node metastases in PTC. Note: Scatter plot shows the correlation of the ratio of BRAFV600E alleles and the number of LNM. Lines represent simple linear regression $\pm 95\%$ confidence interval. Spearman's rho = 0.220, $p < 0.0001$; simple regression adjusted $R^2 = 0.070$, $p < 0.0001$.




Figure 5. Correlation between BRAFV600E alleles ratio and the rate of lymph node metastases in PTC. Note: Scatter plot shows the correlation of the ratio of BRAFV600E alleles and the rate of LNM. Lines represent simple linear regression $\pm 95\%$ confidence interval. Spearman's rho = 0.232, $p < 0.0001$; simple regression adjusted $R^2 = 0.058$, $p < 0.0001$.




Figure 6. Comparison of BRAFV600E alleles ratio between Hashimoto's thyroiditis and those without in PTC. Note: ***: P value <0.001. Vertical scatter plots of the ratio of BRAFV600E alleles grouped by PTC combined Hashimoto's thyroiditis. Lines represent median and interquartile range.

